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Fol/PTX/PLA–TPGS NPsAbstract Paclitaxel is one of the most effective chemotherapeutic agents for treating various types
of cancer. However, the clinical application of paclitaxel in cancer treatment is considerably limited
due to its poor water solubility and low therapeutic index. Thus, it requires an urgent solution to
improve therapeutic efﬁcacy of paclitaxel. In this study, folate decorated paclitaxel loaded
PLA–TPGS nanoparticles were prepared by a modiﬁed emulsiﬁcation/solvent evaporation method.
The obtained nanoparticles were characterized by Field Emission Scanning Electron Microscopy
(FESEM), Fourier Transform Infrared (FTIR) and Dynamic Light Scattering (DLS) method.
The spherical nanoparticles were around 50 nm in size with a narrow size distribution. Targeting
effect of nanoparticles was investigated in vitro on cancer cell line and in vivo on tumor bearing nude
mouse. The results indicated the effective targeting of folate decorated paclitaxel loaded copolymer
nanoparticles on cancer cells both in vitro and in vivo.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Paclitaxel (PTX), isolated from the bark of Taxus brevifolia, is
one of the most effective chemotherapeutic agents for treating
various types of cancers, including ovarian, breast, colon, blad-
der, esophagus, lung, multiple myeloma and Kaposi’s sarcoma
(Singla et al., 2002). However, because of poor aqueous solubil-
ity and low therapeutic index, the clinical application of PTX is
still limited. Current commercial formulations of PTX with
Cremophor EL (Taxol) and albumin (Abraxane) result in
684 H.P. Thu et al.many severe side effects such as hypersensitivity reactions, neu-
rotoxicity, nephrotoxicity, low red blood cell count, stomatitis,
and ocular toxicity (Singla et al., 2002;Miele et al., 2009). Many
attempts, therefore, have been made to develop new drug deliv-
ery systems (DDSs), such as liposomes (Biswas et al., 2012),
polymer–drug conjugates (Meerum Terwogt et al., 2001),
lipid-based nanoparticles (Arica Yegin et al., 2006), and
copolymeric micelles (Zhang et al., 2011). The advantage of
these DDSs compared to conventional DDSs is based on their
nano-size which improves the drug accumulation at the tumor
site in a passive manner, known as the Enhanced Permeability
and Retention (EPR) effect (Dan et al., 2007). Among them,
copolymeric micelles have attached a great deal of attention
thanks to its highly structural stability, small size and drug con-
trolled release (Deng et al., 2012).
Amphiphilic copolymers are composed of hydrophobic and
hydrophilic segments. In aqueous environment, they can self-
assemble into core–shell structures (Miyata et al., 2011), called
copolymeric micelles. The hydrophobic core can be served as
microenvironment for incorporating hydrophobic drugs and
protecting them from chemical degradation while the shell
helps in stabilizing and improving retention time of micelles
in circulatory systems.
In the last decades, biodegradable polymers such as poly-
(caprolactone) (PCL) and poly(lactide) (PLA) were widely
used for the preparation of drug carrier. However, their
hydrophobic characteristics and low degradation rate become
barriers to produce advanced DDSs. Introduction of hydro-
philic polymer such as poly(ethylene glycol) (PEG) or toco-
pheryl polyethylene glycol 1000 succinate (TPGS) can
increase the degradation rate, decrease the hydrophobicity of
these polymer carrier and produce novel copolymeric micelle
systems (Li et al., 2010; Xiao et al., 2010).
For enhancing the intracellular delivery of DDSs to speciﬁc
cancer cell in an active manner, the most widely utilized
approach is to conjugate with targeting ligands, such as folic
acid, aptamers, peptides and antibodies (Byrne et al., 2008).
Among them, folic acid has high binding afﬁnity to folate recep-
tors which are overexpressed on cell surface of many human
tumors while it highly restricted in normal tissue. Conjugation
of folate to DDSs, therefore, facilitated their cellular uptake
on cancer cells via an endocytic process and avoided non-speciﬁc
attacks on normal tissues (Lu andLow, 2002). Pen et.al reported
that PTX nano-formulation using folate decorated PLA–TPGS
copolymer with the size around 300 nm induced better in vitro
targeting effect compared to that of PTX (Pan and Feng,
2008). However, in vivo experiments were not studied. Recent
study showed that the optimal size of drug delivery system
should be 50 nm that balances extravasation, inward permea-
tion inside tumor tissues, tumor cell internalization, and out-
ward diffusion and clearance from tumor to retain the highest
effective drug concentrations in tumors (Tang et al., 2014).
In this study, we prepared folate decorated paclitaxel
loaded PLA–TPGS nanoparticles with the size around 50 nm
and evaluated its targeting effect in vitro on cancer cells and
in vivo on tumor bearing nude mouse.
2. Experimental details
PLA–TPGS copolymer was synthesized by ring-opening
method in the presence of stannous octoate as catalyst asdescribed in our previous report (Fig. 1) (Thu et al., 2013).
Brieﬂy, a given amount of stannous octoate, PLA and TPGS
(1:4 w/w) was dissolved in distilled toluene in an ampoule.
The reaction was carried out for 10 h at 130 C under inert
gas atmosphere in a silicone oil bath. After the reaction time,
the resultant mixture was gently stirred overnight to evaporate
the organic solvent. The product was dissolved in dichloro-
methane and then precipitated in cold methanol in excess to
remove unreacted lactide monomers and TPGS. The ﬁnal pro-
duct was obtained by ﬁltration.
Folate was covalently attached to TPGS molecules through
a modiﬁed process described by Pan and Feng (2008). Firstly,
TPGS was activated with aspartic acid instead of glutamic acid
through the esteriﬁcation between the hydroxyl group of
TPGS and carboxyl group of aspartic acid. Next, folic acid
was animated with ethylene diamine through the formation
of an amide bridge. Finally, the activated TPGS was reacted
with the animated folic acid to form folate attached TPGS
(TPGS–Fol) molecules. All reactions were performed in
dimethyl sulfoxide (DMSO), under ambient temperature and
in the presence of N-Hydroxysuccinimide (NHS) and N,N0-
Dicyclohexylcarbodiimide (DCC) as catalysts (Fig. 1).
Folate decorated paclitaxel loaded PLA–TPGS nanoparti-
cles (Fol/PTX/PLA–TPGS NPs) were prepared by a modiﬁed
emulsiﬁcation/ solvent evaporation process. In brief, the blend
of PLA–TPGS and TPGS–Fol with the ratio of 5:1 (w/w) was
dispersed in an aqueous solution containing 0.03% of TPGS as
an emulsiﬁer. Next, a given amount of PTX dissolved in
dichloromethane (DCM) was added dropwise into the above
solution under magnetic stirring at room temperature. After
48 h stirring, DCM was evaporated and the resulted mixture
was centrifuged at 5000 rpm in 5 min. The obtained transpar-
ent solution was lyophilized. The lyophilized powder was col-
lected and stored at 4 C. Paclitaxel loaded PLA–TPGS
nanoparticles (PTX/PLA–TPGS NPs) as reference sample
were prepared in a similar manner.
The nanoparticles were characterized by FESEM, FTIR
and DLS method. Targeting effect of nanoparticles was inves-
tigated in vitro on cancer cell line and in vivo on tumor bearing
nude mouse.
3. Results and discussion
3.1. Characteristics of nanoparticles
Physicochemical characteristic of nanoparticles was investi-
gated by FTIR (Fig. 2). In the FTIR spectrum of PTX/PLA–
TPGS, peak at 1716 cm1 was attributed to the overlap of
C‚O stretching of PTX at 1712 cm1 and PLA–TPGS at
1756 cm1. Characteristic peaks of PTX at 1648 cm1 (CAC
stretching), 1245 cm1 (CAN stretching), 1074 cm1 (CAO
stretching) (Devi and Gayathri, 2010) were shifted to 1640,
1240, 1069 cm1, respectively. The presence of peak at
1531 cm1 was assigned to the absorption band at 1546 cm1
of aromatic ring of PLA–TPGS. In the FTIR spectrum of
Fol/PTX/PLA–TPGS, compared to that of PTX/PLA–TPGS,
characteristic peaks of PTX/PLA–TPGS at 1716, 1640, 1240,
1069 cm1 were shifted to 1677, 1616, 1230, 1064 cm1, respec-
tively. In addition, the presence of peaks at 1590 cm1 and
1480 cm1 was attributed to NAH bending (1605 cm1) and
the absorption of phenyl ring (1485 cm1) of folic acid
Figure 1 Schematic diagram of polymer synthesis.
Figure 2 FTIR spectra of (1) folic acid, (2) PTX/PLA–TPGS
NPs, and (3) Fol/PTX/PLA–TPGS NPs.
Targetting effect of Fol/PTX/PLA–TPGS NPs 685(Zhang et al., 2008). All these data gave the evidence for the suc-
cess in fabricating Fol/PTX/PLA–TPGS NPs.
Fig. 3 shows the FESEM images and size distribution of
nanoparticles. It can be seen that both PTX/PLA–TPGS
NPs and Fol/PTX/PLA–TPGS NPs were spherical shape.
There was no noticeable difference in size of thesenanoparticles with the size around 50 nm. This result was con-
ﬁrmed by DLS method with the average size of about 55 nm
and a narrow distribution. Recent study showed that nanopar-
ticles with particle size below 50 nm induce the best therapeutic
efﬁciency (Tang et al., 2014).
3.2. In vitro targeting effect of nanoparticles on HeLa cell
In vitro targeting effect of nanoparticles was investigated based
on the quantitative evaluation of morphological change and on
HeLa cell line. Our previous publication demonstrated that
drug loaded PLA–TPGS nanoparticle induced better apoptosis
on cancer cells than free drug through observation of cell mor-
phological change (Thu et al., 2013). HeLa cells were incubated
with PTX, PTX/PLA–TPGS NPs, and Fol/PTX/PLA–TPGS
NPs and observed by inverted microscopy as shown in Fig. 4.
After incubation for 48 h, there were obvious differences in
testing samples.
At the PTX concentration as low as 0.003 lg/ml, the cancer
cells incubated with PTX and PTX/PLA–TPGS NPs had no
morphological change while that change was clearly visualized
in cells incubated with Fol/PTX/PLA–TPGS NPs. The mor-
phological change was observed more and more obviously
when PTX concentration was increased. Compared to PTX,
PTX/PLA–TPGS NPs and Fol/PTX/PLA NPs induced much
more changes. At the PTX concentration of 3 lg/Ml, all cells
were destroyed for Fol/PTX/PLA–TPGS NPs. These
Figure 3 FESEM image and size distribution of (a and b) PTX/PLA–TPGS NPs and (c and d) Fol/PTX/PLA–TPGS NPs.
Figure 4 Morphological change in HeLa cells after 48 h of incubation with different PTX formulations.
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Figure 6 Tumor images of mouse after 42 days of treatment: (a)
control, (b) Free PTX, (c) PTX/PLA–TPGS NPs and (d) Fol/
PTX/PLA–TPGS NPs.
Figure 7 Tumor volume of mouse after 42 days of treatment.
Targetting effect of Fol/PTX/PLA–TPGS NPs 687evidences demonstrated that PTX loaded nanoparticles
induced better targeting effect than free PTX, in which the best
effective targeting belonged to Fol/PTX/PLA NPs. This could
be explained by an increased cell internalization of Fol/PTX/
PLA–TPGS NPs via a folate-receptor-mediated endocytosis
process. Folate decorated system would delivery many drug
molecules when they were internalized by the cell via folate
receptor-mediated endocytosis, causing higher drug concentra-
tion than that of non-folate systems which delivery drug via
passive diffusion. Zhang et.al also found that folate decorated
nanoparticles improve the cellular uptake of drug into cancer
cells (Zhang et al., 2011).
3.3. In vivo targeting effect of nanoparticles
In vivo targeting effect of nanoparticles was evaluated by the
tumor growth inhibition on colorectal tumor bearing nude
mouse. PTX in different formulations (free PTX, PTX/PLA–
TPGS NPs and Fol/PTX/PLA–TPGS NPs) was intravenously
administrated into mouse. The concentration of PTX is the
same in all formulations. Drug administration started on
Day 0 and repeated every 7 days, for a total of six times.
Tumor volume was measured every 7 days until Day 42.
After 7 days of treatment, tumor volume of mouse in PTX
formulations treated groups started becoming different com-
pared to saline treated control group. Groups treated with
PTX/PLA–TPGS NPs and Fol/PTX/PLA–TPGS NPs showed
better tumor inhibitory effect compared with group treated
with free PTX during the treatment time (Fig. 5).
After 42 days of treatment, the Fol/PTX/PLA–TPGS NPs
exhibited the best tumor growth inhibition (Figs. 6 and 7).
Signiﬁcant tumor growth inhibition was probably due to
the combination of two potential mechanisms: (i) Enhanced
Permeability and Retention (EPR) effect; (ii) selective uptake
by cancer cells through receptor- mediated endocytosis. The
EPR effect was mediated by the small size of nanoparticles
(50 nm) promoting the passive permeability at the tumor site
and the PEG residue on the nanoparticle conferring the nano-
particles to remain in circulatory system for a longer duration.
The receptor-mediated endocytosis was mainly due to the pres-
ence of folate moiety on Fol/PTX/PLA–TGPS NPs. After cell
surface binding, the Fol/PTX/PLA–TPGS NPs might be inter-
nalized into the targeted cell via a folate receptor-mediated
endocytosis instead of passive diffusion through the cellFigure 5 Tumor volume development during treatment time.membrane. Consequently, higher PTX concentration would
be achieved inside the cell causing better tumor growth
inhibition.
4. Conclusions
In this study, Paclitaxel loaded nanoparticles composed by
PLA–TPGS copolymer were successfully prepared by a simple
modiﬁed modiﬁcation/solvent evaporation method. Their tar-
geting effect was evaluated by in vitro on cancer cells and
in vivo on tumor bearing mouse. The results showed that PTX
loaded nanoparticles exhibit great advantages compared to free
PTX and the folate decoration signiﬁcantly improve the tar-
geted delivery of drug to cancer cell in both in vitro and in vivo.
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